161 related articles for article (PubMed ID: 33618031)
1. Patient-Derived Mutant Forms of NFE2L2/NRF2 Drive Aggressive Murine Hepatoblastomas.
Wang H; Lu J; Mandel JA; Zhang W; Schwalbe M; Gorka J; Liu Y; Marburger B; Wang J; Ranganathan S; Prochownik EV
Cell Mol Gastroenterol Hepatol; 2021; 12(1):199-228. PubMed ID: 33618031
[TBL] [Abstract][Full Text] [Related]
2. Reconciling the Biological and Transcriptional Variability of Hepatoblastoma with Its Mutational Uniformity.
Prochownik EV
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33919162
[TBL] [Abstract][Full Text] [Related]
3. β-Catenin and Yes-Associated Protein 1 Cooperate in Hepatoblastoma Pathogenesis.
Min Q; Molina L; Li J; Adebayo Michael AO; Russell JO; Preziosi ME; Singh S; Poddar M; Matz-Soja M; Ranganathan S; Bell AW; Gebhardt R; Gaunitz F; Yu J; Tao J; Monga SP
Am J Pathol; 2019 May; 189(5):1091-1104. PubMed ID: 30794807
[TBL] [Abstract][Full Text] [Related]
4. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
[TBL] [Abstract][Full Text] [Related]
5. YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells.
Smith JL; Rodríguez TC; Mou H; Kwan SY; Pratt H; Zhang XO; Cao Y; Liang S; Ozata DM; Yu T; Yin Q; Hazeltine M; Weng Z; Sontheimer EJ; Xue W
Hepatology; 2021 Mar; 73(3):1011-1027. PubMed ID: 32452550
[TBL] [Abstract][Full Text] [Related]
6. Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant
Comerford SA; Hinnant EA; Chen Y; Bansal H; Klapproth S; Rakheja D; Finegold MJ; Lopez-Terrada D; O'Donnell KA; Tomlinson GE; Hammer RE
JCI Insight; 2016 Oct; 1(16):e88549. PubMed ID: 27734029
[TBL] [Abstract][Full Text] [Related]
7. β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice.
Zhang W; Meyfeldt J; Wang H; Kulkarni S; Lu J; Mandel JA; Marburger B; Liu Y; Gorka JE; Ranganathan S; Prochownik EV
J Biol Chem; 2019 Nov; 294(46):17524-17542. PubMed ID: 31597698
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
9. CDK9 is dispensable for YAP-driven hepatoblastoma development.
Chen X; Kiss A; Schaff Z; Evert K; Zhang Y; Zhong S; Wang J; Evert M; Calvisi DF; Chen X
Pediatr Blood Cancer; 2020 May; 67(5):e28221. PubMed ID: 32124532
[TBL] [Abstract][Full Text] [Related]
10. Upregulated YAP promotes oncogenic CTNNB1 expression contributing to molecular pathology of hepatoblastoma.
Lu S; Jiang M; Chen Q; Luo X; Cao Z; Huang H; Zheng M; Du J
Pediatr Blood Cancer; 2022 Sep; 69(9):e29705. PubMed ID: 35404538
[TBL] [Abstract][Full Text] [Related]
11. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
[TBL] [Abstract][Full Text] [Related]
12. Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
Loesch R; Caruso S; Paradis V; Godard C; Gougelet A; Renault G; Picard S; Tanaka I; Renoux-Martin Y; Perret C; Taketo MM; Zucman-Rossi J; Colnot S
J Hepatol; 2022 Aug; 77(2):424-435. PubMed ID: 35257829
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
14. Coordinated Activities of Multiple Myc-dependent and Myc-independent Biosynthetic Pathways in Hepatoblastoma.
Wang H; Lu J; Edmunds LR; Kulkarni S; Dolezal J; Tao J; Ranganathan S; Jackson L; Fromherz M; Beer-Stolz D; Uppala R; Bharathi S; Monga SP; Goetzman ES; Prochownik EV
J Biol Chem; 2016 Dec; 291(51):26241-26251. PubMed ID: 27738108
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
[TBL] [Abstract][Full Text] [Related]
16. Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells.
Konsavage WM; Kyler SL; Rennoll SA; Jin G; Yochum GS
J Biol Chem; 2012 Apr; 287(15):11730-9. PubMed ID: 22337891
[TBL] [Abstract][Full Text] [Related]
17. Quantification of glypican 3, β-catenin and claudin-1 protein expression in hepatoblastoma and paediatric hepatocellular carcinoma by colour deconvolution.
Zhou S; Parham DM; Yung E; Pattengale P; Wang L
Histopathology; 2015 Dec; 67(6):905-13. PubMed ID: 25939253
[TBL] [Abstract][Full Text] [Related]
18. The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans.
Zhang S; Zhang J; Evert K; Li X; Liu P; Kiss A; Schaff Z; Ament C; Zhang Y; Serra M; Evert M; Chen N; Xu F; Chen X; Tao J; Calvisi DF; Cigliano A
Am J Pathol; 2020 Jul; 190(7):1397-1413. PubMed ID: 32283103
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
20. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.
Marquard S; Thomann S; Weiler SME; Bissinger M; Lutz T; Sticht C; Tóth M; de la Torre C; Gretz N; Straub BK; Marquardt J; Schirmacher P; Breuhahn K
Cell Commun Signal; 2020 Oct; 18(1):166. PubMed ID: 33097058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]